Tandem Diabetes Care Inc (NASDAQ:TNDM) saw strong trading volume on Monday . 1,335,557 shares changed hands during mid-day trading, an increase of 232% from the previous session’s volume of 402,477 shares.The stock last traded at $3.11 and had previously closed at $2.52.
Several equities analysts recently commented on the company. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research note on Wednesday, December 6th. Robert W. Baird reiterated a “hold” rating and issued a $3.00 price objective on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Piper Jaffray Companies reiterated a “hold” rating and issued a $15.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Finally, Wedbush reissued an “outperform” rating and set a $17.00 target price (down previously from $50.00) on shares of Tandem Diabetes Care in a report on Tuesday, October 10th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Tandem Diabetes Care currently has an average rating of “Hold” and an average price target of $11.29.
The company has a debt-to-equity ratio of -2.70, a quick ratio of 0.88 and a current ratio of 1.90. The company has a market capitalization of $28.94, a price-to-earnings ratio of -0.15 and a beta of 0.17.
In other news, CEO Kim D. Blickenstaff purchased 285,700 shares of the firm’s stock in a transaction dated Friday, October 13th. The shares were purchased at an average price of $3.50 per share, with a total value of $999,950.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 20.90% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Wedbush Securities Inc. increased its holdings in shares of Tandem Diabetes Care by 88.6% in the third quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock worth $138,000 after purchasing an additional 88,709 shares during the period. Keybank National Association OH increased its holdings in shares of Tandem Diabetes Care by 32.7% in the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock worth $235,000 after purchasing an additional 72,177 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Tandem Diabetes Care by 93.3% in the second quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock worth $465,000 after purchasing an additional 280,551 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Tandem Diabetes Care by 2.7% in the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after purchasing an additional 32,991 shares during the period.
WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2018/01/10/tandem-diabetes-care-tndm-sees-unusually-high-trading-volume.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
What are top analysts saying about Tandem Diabetes Care? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tandem Diabetes Care and related companies.